QT Imaging Holdings, Inc. (QTI) generates news tied to medical device commercialization, breast imaging technology and public company reporting. The company describes itself as focused on breast health management through radiation-free imaging technology, with the Breast Acoustic CT Scanner as its main named system.
QTI news often centers on the progress of its Breast Acoustic CT platform. Relevant company updates include scanner commercialization, distribution and direct commercial activity, development work on reconstruction and quantitative imaging algorithms, clinical workflow, the QTI Precision Pathway cloud platform and collaboration related to a multimodality viewer and quantitative analysis.
Regulatory and quality-related announcements are also important for this issuer because the company operates in a medical device category. QT Imaging has announced FDA clearance for its scanner as an adjunctive breast imaging device for adult women, Israeli Ministry of Health registration for commercialization in Israel and completion of an FDA routine inspection with zero Form 483 observations.
Financial and governance news adds another layer for QTI. The company's releases and filings include quarterly financial results, financing activity, shareholder letters, annual meeting results, executive appointments and equity incentive plan matters. Regular review of QTI news helps connect the company's breast imaging technology claims with commercialization updates, regulatory disclosures and public company governance events.
QT Imaging Holdings (NASDAQ: QTI) reported the results of its Annual Meeting of stockholders held on July 28, 2026. Stockholders approved the election of Professor Zeev Weiner and Bryan Timm as Class II directors through the 2029 Annual Meeting, the appointment of BPM LLP as independent registered public accounting firm for fiscal 2026, and an amendment to the 2024 Equity Incentive Plan to increase authorized shares. According to the company, detailed voting results will be filed on Form 8-K with the SEC.
QT Imaging (Nasdaq: QTI) received regulatory registration from the Israeli Ministry of Health for its Breast Acoustic CT™ Scanner, authorizing commercialization in Israel through February 2, 2028. The registration is based on existing U.S. FDA clearance and applicable Israeli regulatory requirements.
The radiation-free, compression-free 3D breast imaging system uses low-energy sound waves and provides quantitative imaging biomarkers as an adjunctive device for women aged 18 and older. The registration also supports QT Imaging’s collaboration with Rambam Health Care Campus, including a planned clinical study in women with hereditary risk for breast cancer.
QT Imaging (Nasdaq: QTI) completed its first routine FDA inspection with zero Form 483 observations, indicating no cited conditions that may constitute violations of applicable regulations.
The FDA reviewed QT Imaging’s Quality Management System and related operational processes, provided positive feedback on QMS organization and responsiveness, and the company views this as an important operational milestone supporting global commercialization and manufacturing scale-up.
QT Imaging (Nasdaq: QTI) announced that CEO Dr. Raluca Dinu presented the Shiftmaker Award to tennis champion and breast cancer survivor Martina Navratilova during Wimbledon week in London and joined high-profile panels on women’s health, breast health, early detection, and personalized care.
The events, hosted by The Shift, highlight QT Imaging’s commitment to advancing breast health with innovative imaging technologies that provide quantitative information and support more comfortable, patient-centered care.
QT Imaging (Nasdaq: QTI) reported multi-site data supporting strong reproducibility of its Breast Acoustic CT scanner’s quantitative biomarkers. Speed of Sound (SoS) measurements showed less than 1% variability within and across scanners, while volumetric metrics had about 5% variability for Total Breast Volume and 12% for FGV/TBV.
The study, conducted at two clinical sites with five patients per site scanned five times each, suggests this reproducibility can support longitudinal breast imaging and quantitative, data-driven breast health assessment.
QT Imaging (Nasdaq: QTI) received Saudi Food and Drug Authority clearance for its Breast Acoustic CT™ scanner, allowing marketing, sales, and deployment across Saudi Arabia. The approval enables commercial rollout under its exclusive distribution agreement with Gulf Medical Co. and supports QT Imaging’s expansion strategy in the Gulf region.
With regulatory clearances in both Saudi Arabia and the United Arab Emirates, QT Imaging has created a commercial foundation in the two largest healthcare markets in the Gulf, targeting growing demand for radiation-free, compression-free 3D breast imaging.
QT Imaging (Nasdaq: QTI) is expected to be added to the Russell Microcap® Index, based on the preliminary additions list dated May 22, 2026. Final inclusion will follow completion of the 2026 Russell indexes reconstitution and, if affirmed, take effect at the U.S. market open on June 29, 2026.
The Russell Microcap Index tracks the microcap segment of the U.S. equity market and is widely used as a benchmark. Membership, according to QT Imaging, can enhance visibility, broaden exposure to institutional investors and index strategies, and brings automatic inclusion in applicable Russell growth and value style indexes.
QT Imaging (Nasdaq: QTI) closed a previously announced underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants) for gross proceeds of about $10 million.
According to QT Imaging, net proceeds will support working capital and general corporate purposes.
QT Imaging (Nasdaq: QTI) priced an underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants) at $5.00 per share, for expected gross proceeds of $10 million before fees.
The offering is expected to close on or about May 18, 2026. According to QT Imaging, net proceeds will support working capital and general corporate purposes, alongside a recently extended senior secured term loan maturity.
QT Imaging (Nasdaq: QTI) reported first quarter 2026 revenue of $6.5 million, up 133% year-over-year, driven by shipment of 13 Breast Acoustic CT scanners. Gross margin was 41%, and net loss narrowed to $3.4 million from $11.1 million.
The company reaffirmed 2026 revenue guidance of ~$39 million, extended its senior secured term loan maturity to March 31, 2029, secured a dedicated Category III CPT code effective January 2027, obtained FDA 510(k) clearance for scanner enhancements, and confirmed UAE regulatory clearance supporting a multiyear agreement for at least 43 scanners totaling over $24 million.